Drugs Losing Exclusivity in 2030 & Key Intermediates
19 drugs expire in 2030 (public sources), 18 with recorded synthesis routes; key intermediates of 15 drugs are already available through the Unibest supply network. Generic developers typically secure intermediate supply 2–3 years ahead — use this table for shortlisting and RFQ.
| Drug | Tier | Expiry | Indications | Routes | CAS count | Available |
|---|---|---|---|---|---|---|
| Finerenone | C · Watch | 2030 | Systolic heart failure, Diastolic heart failure, Heart failure | 35 | 96 | Available ×96 |
| Venetoclax | B · Position early | 2030 | Acute myeloid leukaemia, Chronic lymphocytic leukaemia | 3 | 31 | Available ×31 |
| Alectinib Hydrochloride | B · Position early | 2030 | Non-small cell lung cancer, Lung cancer | 3 | 30 | Available ×30 |
| Apalutamide | A · Act now | 2030 | Castration-resistant prostate cancer, Prostate cancer | 2 | 20 | Available ×20 |
| Acalabrutinib | A · Act now | 2030 | Mantle cell lymphoma, Chronic lymphocytic leukaemia, Lymphocytic leukaemia | 2 | 14 | Available ×14 |
| Entrectinib | C · Watch | 2030 | Solid tumour, Non-small cell lung cancer | 1 | 14 | Available ×14 |
| Mirogabalin besilate | C · Watch | 2030 | Diabetic neuropathy, Postherpetic neuralgia, Peripheral nervous system disorder | 2 | 14 | Available ×14 |
| Avatrombopag Maleate | C · Watch | 2030 | Thrombocytopenia, Immune thrombocytopenic purpura, Liver disease | 1 | 11 | Available ×11 |
| Tucatinib | C · Watch | 2030 | Breast cancer, Colorectal cancer | 1 | 10 | Available ×10 |
| Dapagliflozin Propanediol/Metformin Hydrochloride | A · Act now | 2030 | Type 2 diabetes | 4 | 16 | Available ×6 |
| Neratinib Maleate | C · Watch | 2030 | Breast cancer | 4 | 30 | Available ×3 |
| Encorafenib | C · Watch | 2030 | Non-small cell lung cancer, Colorectal cancer, Thyroid cancer | 1 | 23 | Available ×2 |
| Vadadustat | C · Watch | 2030 | Chronic renal impairment, Anaemia | 2 | 12 | Available ×1 |
| Omadacycline tosylate | C · Watch | 2030 | Skin and skin structure infection, Community-acquired bacterial pneumonia, Bacterial infection | 3 | 14 | Available ×1 |
| Erdafitinib | C · Watch | 2030 | Urothelial carcinoma, Urinary tract neoplasm | 3 | 18 | Available ×1 |
| Lorlatinib | B · Position early | 2030 | Non-small cell lung cancer | 2 | 20 | - |
| Selinexor | C · Watch | 2030 | Diffuse large B-cell lymphoma, Multiple myeloma | 1 | 7 | - |
| Remimazolam Besilate | C · Watch | 2030 | Sedation, Anaesthesia | 1 | 9 | - |
| Eravacycline | C · Watch | 2030 | COVID-19 | - | - | - |
Frequently asked questions
Which drugs lose exclusivity in 2030?
19 drugs expire in 2030 per public sources: Dapagliflozin Propanediol/Metformin Hydrochloride, Alectinib Hydrochloride, Lorlatinib, Venetoclax, Acalabrutinib, Entrectinib, etc.
When should we start sourcing intermediates for 2030 launches?
Generic developers typically secure development-scale supply 2–3 years before expiry. 15 of the 19 drugs in this table already have on-sale intermediates in the Unibest network; the rest can be RFQ'd per CAS.
Are route and CAS data verified?
All fields are structured data cross-verified from public sources; intermediates carry registry codes and CAS numbers, and every "Available" badge links to real listings.
Source: cross-verified structured fields · Expiry years are public-source estimates; consult individual agencies for authoritative dates · 2026-09-29